Sickle Cell Diseases Treatment Market Size, Share, Growth, Trends, and Industry Analysis: By Disease Type, By Therapy, By Drug Class, Others), By End User, and Region Forecast 2019-2030  

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Sickle Cell Diseases Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: Size, Share, Growth, Trends, and Industry Analysis By Disease Type (Sickle Beta Thalassemia, Sickle Haemoglobin C Disease, Sickle Cell Anaemia, Others), By Therapy (Bone Marrow Transplant, Blood Transfusion, Gene Therapy), By Drug Class (Antibiotics, Analgesics, Antimetabolite (Hydroxyurea), Others), By End User, (Hospitals, Retail Pharmacies, Others) and Region Forecast 2019-2030  

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Sickle Cell Disease Treatment Market size was valued at US$ 3.6 billion in 2023 and is poised to grow at a CAGR of 14.09% from 2024-2030. Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.

Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCDs. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesnt carry those genes.

Key Developments

  • In July 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease
  • In 2016, Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases

summary download arrow Download Free Sample

Sickle Cell Diseases Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

14.09%

Largest Market

Asia-Pacific

Fastest Growing Market

North America

Sickle Cell Disease Treatment Market Dynamics

Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.

Sickle Cell Diseases Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 3.6 billion

Market CAGR

14.09%

By Disease Type

  • Sickle Beta Thalassemia
  • Sickle Haemoglobin C Disease
  • Sickle Cell Anaemia
  • Others

By Therapy

  • Bone Marrow Transplant
  • Blood Transfusion
  • Gene Therapy

By Drug Class

  • Antibiotics
  • Analgesics
  • Antimetabolite (Hydroxyurea)
  • Others

By End User

  • Hospitals
  • Retail Pharmacies
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The sickle cell diseases treatment market provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global sickle cell diseases treatment market size was valued at US$ 3.6 billion in 2023 and is projected to grow at a CAGR of 14.09% from 2024 to 2030.

Increasing Prevalence of Sickle Cell Disease

North America is the fastest-growing for sickle cell diseases treatment market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Sickle Cell Diseases Treatment Market Introduction 
2.1.Global Sickle Cell Diseases Treatment Market  - Taxonomy
2.2.Global Sickle Cell Diseases Treatment Market  - Definitions
2.2.1.Disease Type
2.2.2.Therapy
2.2.3.Drug Class
2.2.4.Region
3.Global Sickle Cell Diseases Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Sickle Cell Diseases Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Sickle Cell Diseases Treatment Market  By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Sickle Beta Thalassemia
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Sickle Haemoglobin C Disease
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sickle Cell Anaemia
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Sickle Cell Diseases Treatment Market  By Therapy, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Bone Marrow Transplant
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Blood Transfusion
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Gene Therapy
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Sickle Cell Diseases Treatment Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Antibiotics
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Analgesics
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Antimetabolite (Hydroxyurea)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Sickle Cell Diseases Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Sickle Beta Thalassemia
9.1.2.Sickle Haemoglobin C Disease
9.1.3.Sickle Cell Anaemia
9.1.4.Others
9.2.  Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Bone Marrow Transplant
9.2.2.Blood Transfusion
9.2.3.Gene Therapy
9.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Antibiotics
9.3.2.Analgesics
9.3.3.Antimetabolite (Hydroxyurea)
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Disease Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Sickle Beta Thalassemia
10.1.2.Sickle Haemoglobin C Disease
10.1.3.Sickle Cell Anaemia
10.1.4.Others
10.2.  Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Bone Marrow Transplant
10.2.2.Blood Transfusion
10.2.3.Gene Therapy
10.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Antibiotics
10.3.2.Analgesics
10.3.3.Antimetabolite (Hydroxyurea)
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Disease Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Sickle Beta Thalassemia
11.1.2.Sickle Haemoglobin C Disease
11.1.3.Sickle Cell Anaemia
11.1.4.Others
11.2.  Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Bone Marrow Transplant
11.2.2.Blood Transfusion
11.2.3.Gene Therapy
11.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Antibiotics
11.3.2.Analgesics
11.3.3.Antimetabolite (Hydroxyurea)
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Disease Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Sickle Beta Thalassemia
12.1.2.Sickle Haemoglobin C Disease
12.1.3.Sickle Cell Anaemia
12.1.4.Others
12.2.  Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Bone Marrow Transplant
12.2.2.Blood Transfusion
12.2.3.Gene Therapy
12.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Antibiotics
12.3.2.Analgesics
12.3.3.Antimetabolite (Hydroxyurea)
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Sickle Cell Diseases Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Disease Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Sickle Beta Thalassemia
13.1.2.Sickle Haemoglobin C Disease
13.1.3.Sickle Cell Anaemia
13.1.4.Others
13.2.  Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Bone Marrow Transplant
13.2.2.Blood Transfusion
13.2.3.Gene Therapy
13.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Antibiotics
13.3.2.Analgesics
13.3.3.Antimetabolite (Hydroxyurea)
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Biogen
14.2.2.Gamida Cell
14.2.3.Genetix Pharmaceuticals Inc.
14.2.4.Sangamo Biosciences
14.2.5.Alnylam Pharmaceuticals, Inc.
14.2.6.Acceleron Pharma
14.2.7.Global Blood Therapeutics Inc.
14.2.8.Emmaus Medical, Inc.
14.2.9.Novartis AG
14.2.10.Bristol-Myers Squibb Company
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Biogen
  • Gamida Cell
  • Genetix Pharmaceuticals Inc.
  • Sangamo Biosciences
  • Alnylam Pharmaceuticals, Inc.
  • Acceleron Pharma
  • Global Blood Therapeutics Inc.
  • Emmaus Medical, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company

Related Industry Reports

Infectious Diseases Point Of Care Poc Diagnostic Market

Sickle Cell Disease Pipeline Drugs Assessment

Global Foodborne Diseases Treatment Market

Global Psoriasis Treatment Market